| Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. | |
| | |
MedLine Citation:
|
PMID: 20367555 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: This study tested the hypothesis that the addition of full-dose atorvastatin (80 mg/day) to conventional medical treatment could reduce ischaemic recurrences after non-ST-elevation acute myocardial infarction (NSTE-AMI) in patients with severe and diffuse coronary artery disease (CAD) not amenable to any form of mechanical revascularisation. METHODS AND RESULTS: The study was an open-label, randomised, controlled, blinded end-point classification trial, employing the PROBE (Prospective Open Treatment and Blinded End Point Evaluation) design. A total of 290 patients (mean age 74.6 +/- 9.6 years) with NSTE-AMI and angiographic evidence of severe and diffuse CAD, not amenable to revascularisation by either coronary surgery or angioplasty, were randomised to atorvastatin 80 mg/day (n = 144) or conventional medical treatment (n = 146). A primary end point event (combination of cardiovascular death, non-fatal acute myocardial reinfarction and disabling stroke within 12 months of randomisation) occurred in 16.0% of patients treated with atorvastatin 80 mg/day and in 26.7% of patients receiving conventional treatment (HR 0.56; 95% CI 0.33-0.93, p = 0.027). The study was not blinded. Consequently, a bias in the assessment of clinical outcome cannot be completely excluded. CONCLUSIONS: In conclusion, when compared with a conventional treatment strategy, full-dose therapy with atorvastatin 80 mg/day provides greater protection against ischaemic recurrences after NSTE-AMI in patients with severe, diffuse, non-revascularisable CAD. |
| | |
Authors:
|
Furio Colivicchi; Marco Tubaro; David Mocini; Alberto Genovesi Ebert; Stefano Strano; Giovanni Melina; Massimo Uguccioni; Massimo Santini |
Related Documents
:
|
20510215 - Cardiac magnetic resonance with edema imaging identifies myocardium at risk and predict... 3738555 - The impact of the family and lay others on care-seeking during life-threatening episode... 3195475 - Risk of developing an acute myocardial infarction or sudden coronary death in patients ... 19696685 - Relation of left ventricular mass and concentric remodeling to extent of coronary arter... 20022645 - Plasma ca-125 level is related to both sides of the heart: a retrospective analysis. 11276095 - Advances in human cardiac 31p-mr spectroscopy: sloop and clinical applications. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Current medical research and opinion Volume: 26 ISSN: 1473-4877 ISO Abbreviation: Curr Med Res Opin Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-17 Completed Date: 2010-09-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0351014 Medline TA: Curr Med Res Opin Country: England |
Other Details:
|
Languages: eng Pagination: 1277-84 Citation Subset: IM |
Affiliation:
|
Cardiology Division, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy. f.colivicchi@sanfilipponeri.roma.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Anticholesteremic Agents / administration & dosage*, pharmacology Coronary Artery Disease / drug therapy* Dose-Response Relationship, Drug Female Heptanoic Acids / administration & dosage*, pharmacology Humans Italy Male Myocardial Infarction* Myocardial Ischemia / prevention & control Pyrroles / administration & dosage*, pharmacology Recurrence Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Heptanoic Acids; 0/Pyrroles; 110862-48-1/atorvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Brain-specific angiogenesis inhibitor 2 (BAI2) may be activated by proteolytic processing.
Next Document: Tumour perfusion assessment during regional hyperthermia treatment: comparison of temperature probe ...